Alirocumab has been studied in 58 papers since 2017: 9 trials and 24 observational studies in people, 1 in animals, 20 reviews; 49 in the past year. It is an approved medicine. The newest story, Nov 9, 2026: “Weighted blood marker better predicted heart and stroke risk”.
Alirocumab lowers cardiovascular events and LDL cholesterol in humans, replicated by independent labs; a trial reports fewer deaths at age 65 or older. An observational comparison of monthly versus biweekly dosing finds no clear cardiovascular-event link. Papers declare developer ties; aging-related trials are registered, while most trials across uses are developer-sponsored and some ended over a year ago without posted results.
35 findings in 22 papers from 2019 to 2026, 13 of them since August 2026
Independent labs found the same change in people. 16 independent labs in 12 countries; 66 trials, 12 about aging, 10 with no results posted.
“Across BMI categories, alirocumab hazard ratios for MACE were 0.98, 0.85, 0.80, and 0.74 (trend interaction p=0.071).”
Humans: replicated by independent labs. Mice: a single group. Cells and worms or flies: nothing yet.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
About aging: the drug’s trials about aging. The total counts its trials for every use.
No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
16 independent labs in 12 countries
2 findings against
66 trials, 12 about aging, 10 with no results posted
265 peopleIn patients with acute myocardial infarction
Circulation. Genomic and precision medicine, Feb 10, 2026
What did studies of alirocumab find?
17
Studies of alirocumab measured 17 outcomes; the most studied are LDL cholesterol (7 studies), major adverse cardiovascular events (2) and lipoprotein (2).
LDL cholesterol
↓downin humans7−34%
7 studies
Alirocumab decreases LDL cholesterol in humans.
“Between-group comparison of LDL-C changes revealed a statistically significant difference (p < 0.001), with a more pronounced reduction in LDL-C in the Alirocumab group.”
Alirocumab decreases major adverse cardiovascular events in humans (patients aged ≥65 years; consistent with <65 years) (HR 0.78 (0.68-0.91) for ≥65 years).
“Relative risk reductions were consistent for patients ≥65 vs. <65 years for MACE [hazard ratio (HR) 0.78, 95% confidence interval (CI) 0.68-0.91 vs. 0.89, 0.80-1.00; Pinteraction = 0.19]”
Human trialpatients aged ≥65 years; consistent with <65 years
Alirocumab was not clearly linked with major adverse cardiovascular events in humans (Hong Kong patients prescribed alirocumab) (Biweekly 8.6% versus monthly 8.9%; p=0.829).
“At 12 months, there was no statistically significant difference in the incidence of MACE between groups (8.6% vs. 8.9%; p=0.829).”
HumansHong Kong patients prescribed alirocumabmonthly versus biweekly12 monthsn = 2,012
Alirocumab decreases ceramide in patients with acute myocardial infarction.
“Lipidomics identified more pronounced reductions in cholesteryl esters, ceramides, sphingomyelins, phosphatidylcholines, triglycerides, and diglycerides in PCSK9 mAb-treated patients with MI.”
Human trialin patients with acute myocardial infarctionplasma
Studies link alirocumab with 8 measures, among them major adverse cardiovascular events, mortality and LDL cholesterol target attainment.
Major adverse cardiovascular events
↓downin humans2HR 0.98
2 studies
Alirocumab lowers the risk of major adverse cardiovascular events in humans (HRs 0.98, 0.85, 0.80, and 0.74 across increasing BMI categories; trend interaction p=0.071).
“Across BMI categories, alirocumab hazard ratios for MACE were 0.98, 0.85, 0.80, and 0.74 (trend interaction p=0.071).”
Human trialversus placebo after acute coronary syndrome; BMI categories <25, 25–<30, 30–<35, and ≥35 kg/m275 mg with protocol-driven up-titration to 150 mgn = 18,924
Alirocumab is associated with mortality in humans (Compared with evolocumab in patients with atherosclerotic heart disease and dyslipidemia) (3 years: HR 1.358 (95% CI 1.200–1.536); 5 years: HR 1.325 (1.193–1.470)).
“mortality favored evolocumab at 3 years (HR 1.358, 95% CI 1.200-1.536) and 5 years (HR 1.325, 95% CI 1.193-1.470).”
HumansCompared with evolocumab in patients with atherosclerotic heart disease and dyslipidemia3 and 5 years
Alirocumab is associated with LDL cholesterol target attainment in humans (Hong Kong patients prescribed alirocumab) (<1.4 mmol/L: 64.8% versus 54.0%, p=<0.001; <1.8 mmol/L: 75.5% versus 66.2%, p=0.002; >50% reduction: 56.6% versus 48.0%, p=0.007).
“higher proportions achieving LDL-C targets at all thresholds:”
HumansHong Kong patients prescribed alirocumabmonthly versus biweekly12 monthsn = 2,012
Composite risk of all-cause death, myocardial infarction, or ischemic stroke
↓downin humans1
1 study
Alirocumab is associated with composite risk of all-cause death, myocardial infarction, or ischemic stroke in humans (Observed ARR 6.0% (95% CI 3.0–9.0%); RRR 38.7% (18.7–58.7%); g-computation ARR 5.9% (3.3–8.2%), RRR 38.6% (21.0–50.7%); all p<0.001).
“alirocumab was associated with lower 4-year risk of all-cause death, MI, or ischemic stroke”
HumansEstablished atherosclerotic cardiovascular disease without prior myocardial infarction, unstable angina, or ischemic stroke; compared with no PCSK9 inhibitor75 mg Q2W, 150 mg Q2W, or 300 mg Q4W4 years62% male among alirocumab users; 63% among comparatorssn = 4,008
Rehospitalization for any and cardiovascular reasons
↓downin humans1
1 study
Alirocumab is associated with rehospitalization for any and cardiovascular reasons in humans (More than three-fold decrease).
“A more than three-fold decrease in the need for rehospitalizations for any and cardiovascular reasons was noted among patients with an earlier start of PCSK9-targeted therapy.”
HumansEarlier versus later initiation after ACS, as part of multicomponent lipid-lowering therapy18 months after ACS
Alirocumab is associated with target LDL cholesterol attainment in humans (Earlier versus later initiation: 83.3% versus 40.0% at 6 months; 88.9% versus 55.0% at 12 months).
“the proportions of those who achieved the target low-density lipoprotein cholesterol after 6 and 12 months, respectively, were 40.0 and 83.3% (p=0.008), 55.0 and 88.9% (p=0.024).”
HumansAlirocumab initiation within 3 months versus 3 or more months after ACS, as part of multicomponent lipid-lowering therapy6 and 12 months after ACS
Alirocumab is linked with a higher risk of musculoskeletal and connective tissue disorders in humans (compared with all other drugs in FAERS) (ROR1 = 2.626, 95% CI 2.552-2.702).
“both alirocumab and evolocumab had a significant signal in "musculoskeletal and connective tissue disorders"”
Alirocumab reduces cardiovascular events and mortality in adults aged 65 or older in a human trial; independent labs also report fewer cardiovascular events in humans. A cohort finds no clear cardiovascular-event difference between monthly and biweekly dosing. Most registered trials across uses are sponsored by Sanofi or Regeneron; some ended over a year ago without posted results.
A human trial of alirocumab reports carotid plaque regression at 12 months and reduced intraplaque neovascularization and LDL-C at six months; a review describes fewer major adverse cardiovascular events. Direct findings come from one lab. Regeneron and Sanofi sponsor 41 of 58 registered trials; 12 trials ended over a year ago without posted results or papers citing them.
Absolute reductions in the risk of heart and stroke events with alirocumab versus placebo ranged from 0.5 to 4 percentage points across the marker’s range.Absolute reductions in the risk of heart and stroke events with alirocumab versus placebo ranged from 0.5 to 4 percentage points across the marker’s range.
Over three years, deaths occurred in 1.4% of evolocumab users versus 2.7% of alirocumab users across 2,610 matched pairs.Over three years, deaths occurred in 1.4% of evolocumab users versus 2.7% of alirocumab users across 2,610 matched pairs.